CN107848979A - 乐伐替尼甲磺酸盐的新晶型及其制备方法 - Google Patents

乐伐替尼甲磺酸盐的新晶型及其制备方法 Download PDF

Info

Publication number
CN107848979A
CN107848979A CN201680036277.7A CN201680036277A CN107848979A CN 107848979 A CN107848979 A CN 107848979A CN 201680036277 A CN201680036277 A CN 201680036277A CN 107848979 A CN107848979 A CN 107848979A
Authority
CN
China
Prior art keywords
crystal form
formula
compound
preparation
mesylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680036277.7A
Other languages
English (en)
Chinese (zh)
Inventor
陈敏华
张炎锋
刁小娟
张晓宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing F&s Pharmatech Co ltd
Nanjing Obsidian And Medical Science And Technology Co ltd
Original Assignee
Crystal Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmatech Co Ltd filed Critical Crystal Pharmatech Co Ltd
Priority to CN202110477564.4A priority Critical patent/CN113527203B/zh
Publication of CN107848979A publication Critical patent/CN107848979A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/02—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C255/03—Mononitriles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
CN201680036277.7A 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的新晶型及其制备方法 Pending CN107848979A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110477564.4A CN113527203B (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的晶型及其制备方法和用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510263300 2015-05-21
PCT/CN2016/085360 WO2016184436A1 (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的新晶型及其制备方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110477564.4A Division CN113527203B (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的晶型及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN107848979A true CN107848979A (zh) 2018-03-27

Family

ID=57319484

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680036277.7A Pending CN107848979A (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的新晶型及其制备方法
CN202110477564.4A Active CN113527203B (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的晶型及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110477564.4A Active CN113527203B (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的晶型及其制备方法和用途

Country Status (7)

Country Link
US (1) US10246418B2 (cg-RX-API-DMAC7.html)
EP (1) EP3287444A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018520205A (cg-RX-API-DMAC7.html)
CN (2) CN107848979A (cg-RX-API-DMAC7.html)
IL (1) IL255738A (cg-RX-API-DMAC7.html)
MX (1) MX2017014799A (cg-RX-API-DMAC7.html)
WO (1) WO2016184436A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技（苏州）有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN112174886A (zh) * 2019-07-02 2021-01-05 成都苑东生物制药股份有限公司 一种甲磺酸乐伐替尼晶型x的制备方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
EP3202799B1 (en) 2014-09-30 2021-08-25 LG Chem, Ltd. Block copolymer
US10562855B2 (en) * 2016-06-08 2020-02-18 Crystal Pharmatech Co., Ltd. Crystalline form of lenvantinib mesylate and process of preparation thereof
CN110248660A (zh) * 2016-12-29 2019-09-17 雷迪博士实验室有限公司 甲磺酸乐伐替尼的固态形式
CN110494423B (zh) * 2017-04-25 2022-04-26 苏州科睿思制药有限公司 乐伐替尼甲磺酸盐的新晶型及其制备方法
US11236050B2 (en) * 2017-12-09 2022-02-01 Msn Laboratories Private Limited, R&D Center Polymorphs of 4-[3-chloro-4-(n′-cyclopropyl ureido)phenoxy] -7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof
CN109988112A (zh) * 2017-12-29 2019-07-09 四川科伦药物研究院有限公司 仑伐替尼甲磺酸盐的晶型及其制备方法
WO2019228485A1 (zh) * 2018-06-01 2019-12-05 成都苑东生物制药股份有限公司 一种甲磺酸乐伐替尼新晶型及其制备方法
CN110818634B (zh) * 2018-08-13 2021-11-30 上海新礼泰药业有限公司 甲磺酸乐伐替尼的精制方法
EP3620453A1 (en) 2018-09-07 2020-03-11 Indena S.p.A. New crystal form of lenvatinib
CN111689897B (zh) * 2019-03-13 2024-02-06 齐鲁制药有限公司 一种高纯度甲磺酸乐伐替尼晶型c的制备方法
CN109867626A (zh) * 2019-04-18 2019-06-11 安礼特（上海）医药科技有限公司 一种甲磺酸仑伐替尼多晶型物及其制备方法
CN110229103A (zh) * 2019-06-27 2019-09-13 尚科生物医药（上海）有限公司 一种乐伐替尼甲磺酸盐晶型b的制备方法
EP3996707A4 (en) 2019-07-08 2023-02-22 Rezolute, Inc. CRYSTALLINE FORMS OF PLASMACALLICREIN INHIBITORS
CN110563644A (zh) * 2019-10-30 2019-12-13 北京赛思源生物医药技术有限公司 一种仑伐替尼甲磺酸盐的新晶型
CN112851580A (zh) 2019-11-12 2021-05-28 深圳博澜医药有限责任公司 乐伐替尼甲磺酸盐的晶型及其方法
CN117945999B (zh) * 2020-01-19 2025-08-22 重庆医药工业研究院有限责任公司 一种氟伐替尼或甲磺酸盐的晶型及其制备方法
WO2021213453A1 (zh) * 2020-04-24 2021-10-28 成都苑东生物制药股份有限公司 一种甲磺酸仑伐替尼晶型xi及其制备方法
CN112939859B (zh) * 2021-02-03 2022-03-11 南京方生和医药科技有限公司 甲磺酸仑伐替尼m晶型的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001629A (zh) * 2004-09-17 2007-07-18 卫材R&D管理有限公司 药物组合物
CN100569753C (zh) * 2003-12-25 2009-12-16 卫材R&D管理有限公司 4-(3-氯-4-(环丙基氨基羰基)氨基苯氧基)-7-甲氧基-6-喹啉羧酰胺的甲磺酸盐的结晶（c）及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
KR100951607B1 (ko) * 2005-06-23 2010-04-09 에자이 알앤드디 매니지먼트 가부시키가이샤 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 비정질 염 및 그 제조방법
CA2771403C (en) * 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100569753C (zh) * 2003-12-25 2009-12-16 卫材R&D管理有限公司 4-(3-氯-4-(环丙基氨基羰基)氨基苯氧基)-7-甲氧基-6-喹啉羧酰胺的甲磺酸盐的结晶（c）及其制备方法
CN101001629A (zh) * 2004-09-17 2007-07-18 卫材R&D管理有限公司 药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
石远凯: "《中国肿瘤内科进展 中国肿瘤医师教育 2015年》", 31 July 2015, 中国协和医科大学出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技（苏州）有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN112174886A (zh) * 2019-07-02 2021-01-05 成都苑东生物制药股份有限公司 一种甲磺酸乐伐替尼晶型x的制备方法

Also Published As

Publication number Publication date
WO2016184436A1 (zh) 2016-11-24
CN113527203B (zh) 2023-07-25
US20180155291A1 (en) 2018-06-07
IL255738A (en) 2018-01-31
JP2018520205A (ja) 2018-07-26
US10246418B2 (en) 2019-04-02
EP3287444A1 (en) 2018-02-28
MX2017014799A (es) 2023-02-23
CN113527203A (zh) 2021-10-22
EP3287444A4 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
CN113527203B (zh) 乐伐替尼甲磺酸盐的晶型及其制备方法和用途
CN106432231B (zh) Azd9291的药用盐、及其晶型和制备方法
CN105111215B (zh) 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
EP2878598B1 (en) Crystalline form of 4-[5-(pyridine-4-yl)-1h-1,2,4-triazole-3-yl]pyridine-2-carbonitrile
CN105753789B (zh) 奥拉帕尼与尿素的共晶及其制备方法
RS52754B (sr) MALAT SO N-(4- {[6,7-BIS(METILOKSI)HINOLIN-4-IL]OKSI}FENIL-N'- (4-FLUOROFENIL) CIKLOPROPAN-1,1-DIKARBOKSAMID-a, I NJENI KRISTALNI OBLICI ZA LEČENJE KARCINOMA
CN107428727A (zh) 来那替尼马来酸盐的新晶型及其制备方法
TWI816791B (zh) 一種稠環嘧啶類化合物的鹽、晶型及其製備方法和應用
CN105218484A (zh) 酒石酸卡利拉嗪及其制备方法和医药用途
CN105801476A (zh) 阿帕替尼甲磺酸盐ii晶型及其制备方法和应用
CN108341773A (zh) 卡博替尼苹果酸盐的晶型ii
CN106279151A (zh) 5-(2-(8-((2,6-二甲基苄基)氨基)-2,3-二甲基咪唑并[1,2-a]吡啶-6-甲酰胺基)乙氧基)-5-氧代戊酸的固体形式及其制备方法
CN110903239A (zh) 乐伐替尼甲磺酸盐的新晶型及其制备方法
JP6752822B2 (ja) キナゾリンクロチル化合物二マレイン酸塩結晶、ならびに、その調製方法および使用
CN105061420A (zh) 一种jak抑制剂的晶型及其制备方法和应用
JP2022525125A (ja) ブレイアコニチンａのｅ結晶形及びその製造方法と応用
CN104130207B (zh) 阿考替胺氢溴酸盐水合物及其晶型的制备方法
EP3168212B1 (en) Crystal form a of apatinib mesylate, preparation method therefor, and application thereof
CN113004279A (zh) 一种控制含parp抑制剂倍半水合物产物的含水量的方法
CN109776543A (zh) 依鲁替尼盐、其晶体、制备方法、药物组合物及应用
WO2022171117A1 (zh) 含氮稠杂环化合物的盐、晶型及其制备方法、药物组合物和用途
TWI707851B (zh) 哌嗪化合物的新穎結晶
CN114096541B (zh) 一种p53-MDM2抑制剂的晶型及其制备方法
CN108250137A (zh) 阿帕替尼c晶型及其制备方法和应用
CN103819428B (zh) 7β,10β-二甲氧基多西紫杉醇的溶剂化物的晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180507

Address after: 211800 2 building, research centre, 29, bu Yue Road, Qiaolin street, Pukou District, Nanjing, Jiangsu.

Applicant after: Nanjing Fang Sheng and Pharmaceutical Technology Co., Ltd.

Address before: 215123 Biological Park B4, No. 218 Xing Hu Street, Suzhou Industrial Park, Jiangsu

Applicant before: Crystal Pharmatech Co., Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180620

Address after: 211800 12 -283, No. 29, bu Yue Road, Qiaolin street, Pukou District, Nanjing, Jiangsu.

Applicant after: Nanjing obsidian and medical science and Technology Co., Ltd.

Address before: 211800 2 building, research centre, 29, bu Yue Road, Qiaolin street, Pukou District, Nanjing, Jiangsu.

Applicant before: Nanjing Fang Sheng and Pharmaceutical Technology Co., Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210317

Address after: No.12-1800, Building 29, yulinkou street, puqiao District, Nanjing City, Jiangsu Province

Applicant after: NANJING F&S PHARMATECH Co.,Ltd.

Applicant after: Nanjing obsidian and medical science and Technology Co.,Ltd.

Address before: 211800 12 -283, No. 29, bu Yue Road, Qiaolin street, Pukou District, Nanjing, Jiangsu.

Applicant before: Nanjing obsidian and medical science and Technology Co.,Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180327